

FORM PTO-1449

U.S. DEPARTMENT OF COMMERCE
PATENT AND TRADEMARK OFFICEATTY. DOCKET NO.
ELITRA.009AAPPLICATION NO.
09/741,669SUPPLEMENTAL
INFORMATION DISCLOSURE STATEMENT
BY APPLICANT

(USE SEVERAL SHEETS IF NECESSARY)

APPLICANT
Forsyth, et al.FILING DATE
December 19, 2000GROUP
1634

U.S. PATENT DOCUMENTS

EXAMINER INITIAL	DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS	FILING DATE (IF APPROPRIATE)

FOREIGN PATENT DOCUMENTS

EXAMINER INITIAL	DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUBCLASS	TRANSLATION	
						YES	NO

EXAMINER
INITIAL

OTHER DOCUMENTS (INCLUDING AUTHOR, TITLE, DATE, PERTINENT PAGES, ETC.)

<i>m</i>	1	Branch, A. D. 1998. A good antisense molecule is hard to find. <i>TIBS</i> , 23:45-50.
<i>J</i>	2	Dove, A. 2002. Antisense and sensibility. <i>Nature Biotechnology</i> , 20:121-124.
<i>J</i>	3	Gucev, et al. 1998. Insulin-like growth factor binding protein 3 mediates retinoic acid- and transforming growth factor β 2-induced growth inhibition in human breast cancer cells. <i>Cancer Research</i> , 58(7):1545-1550.
<i>J</i>	4	Lebedeva, et al. 2001. Antisense oligonucleotides: Promise and reality. <i>Annu. Rev. Pharmacol. Toxicol.</i> , 41:403-419.
<i>✓</i>	5	Sofia, et al. *Analysis of the <i>Escherichia coli</i> genome. V. DNA sequence of the region from 76.0 to 81.5 minutes. Database accession no. XP-002228916.

S:\DOCS\DOH\DOH-7344.DOC:dmb
031703

EXAMINER

DATE CONSIDERED

12/31/2003

*EXAMINER: INITIAL IF CITATION CONSIDERED, WHETHER OR NOT CITATION IS IN CONFORMANCE WITH MPEP 609; DRAW LINE THROUGH CITATION IF NOT IN CONFORMANCE AND NOT CONSIDERED, INCLUDE COPY OF THIS FORM WITH NEXT COMMUNICATION TO APPLICANT.